PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability.
Christina FevgaChristelle TessonAna Carreras MascaroThomas CourtinRiaan van CollerSalma SakkaFederico FerraroNouha FarhatSoraya BardienMariem DamakJonathan CarrMélanie FerrienValerie BoumeesterJasmijn HundscheidNicola GrillenzoniIrini A KessissoglouDemy J S KuipersMarialuisa Quadrinull nullnull nullJean Christophe CorvolChokri MhiriBassem A HassanGuido J BreedveldSuzanne LesageWim MandemakersAlexis BriceVincenzo BonifatiPublished in: Brain : a journal of neurology (2022)
The protein phosphatase 2A complex (PP2A), the major Ser/Thr phosphatase in the brain, is involved in a number of signaling pathways and functions, including the regulation of crucial proteins for neurodegeneration, such as alpha-synuclein, tau, and LRRK2. Here, we report the identification of variants in the PTPA/PPP2R4 gene, encoding a major PP2A activator, in two families with early-onset parkinsonism and intellectual disability. We carried out clinical studies and genetic analyses, including genome-wide linkage analysis, whole-exome sequencing, and Sanger sequencing of candidate variants. We next performed functional studies on the disease-associated variants in cultured cells and knock-down of ptpa in Drosophila melanogaster. We first identified a homozygous PTPA variant, c.893T > G (p.Met298Arg), in patients from a South African family with early-onset parkinsonism and intellectual disability. Screening of a large series of additional families yielded a second homozygous variant, c.512C > A (p.Ala171Asp), in a Libyan family with a similar phenotype. Both variants co-segregate with disease in the respective families. The affected subjects display juvenile-onset parkinsonism and intellectual disability. The motor symptoms were responsive to treatment with levodopa and deep brain stimulation of the subthalamic nucleus. In overexpression studies, both the PTPA p.Ala171Asp and p.Met298Arg variants were associated with decreased PTPA RNA stability and decreased PTPA protein levels; the p.Ala171Asp variant additionally displayed decreased PTPA protein stability. Crucially, expression of both variants was associated with decreased PP2A complex levels and impaired PP2A phosphatase activation. PTPA ortholog knock-down in Drosophila neurons induced a significant impairment of locomotion in the climbing test. This defect was age-dependent and fully reversed by L-DOPA treatment. We conclude that bi-allelic missense PTPA variants associated with impaired activation of the PP2A phosphatase cause autosomal recessive early-onset parkinsonism with intellectual disability. Our findings might also provide new insights for understanding the role of the PP2A complex in the pathogenesis of more common forms of neurodegeneration.
Keyphrases
- intellectual disability
- early onset
- copy number
- parkinson disease
- autism spectrum disorder
- deep brain stimulation
- late onset
- genome wide
- drug induced
- dna methylation
- obsessive compulsive disorder
- binding protein
- induced apoptosis
- drosophila melanogaster
- gene expression
- poor prognosis
- chronic kidney disease
- endothelial cells
- end stage renal disease
- single cell
- transcription factor
- hepatitis c virus
- depressive symptoms
- brain injury
- cell death
- epithelial mesenchymal transition
- data analysis
- endoplasmic reticulum stress
- cancer therapy
- prognostic factors
- case control
- nucleic acid